Among our predicted drugs, as the only predicted CD27 agonistic antibody, Varlilumab has been previously used to explore the treatment of a wide range of hematologic and solid tumors, e.g., in early clinical trials, varlilumab demonstrated preliminary efficacy against hematologic and ovarian cancers (65, 66). This evidence concerns the gene CD27 and ovarian carcinoma.